FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022
Paris, France, September 22, 2022 – Invectys Inc. is a clinical-stage immunotherapy company dedicated to the development of a new generation of products for cancer patients. Headquartered in Houston and with R&D facilities in Paris, Invectys will participate in the Abbvie Partnering Day in Paris, France, on October 4th, 2022, announced François Lescure, General Manager of its R&D branch in France.
About Invectys
Invectys, transforming innovative immunotherapies to eradicate cancer, is a clinical stage immuno-oncology company spun-out of the world-renowned Pasteur Institute in Paris. Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston), whose lead project is the development of a first-in-human HLA-G /CAR-T at MD Anderson Cancer Center. Since 2010, Invectys has raised over $63 million in private funds to develop two innovative platforms of immunotherapy products that target “universal” tumor antigens. Invectys has also received a grant of $14.2 million from the Cancer Prevention and Research Institute of Texas.
Contact:
Invectys, SAS – François Lescure, General Manager
contact@invectys.com
